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We read with interest the recent commentary by Friedrich
and coworkers [1], in which they consider whether the
current evidence supports treatment for severe sepsis with
drotrecogin alfa (activated). They conclude that the survival
benefit is weak in patients with severe sepsis treated with
activated protein C (APC) [1]. However, this conclusion has a
number of limitations.
First, the authors have summated the individual studies by
using a random effects model. Although the random effects
model is generally used in the presence of significant hetero-
geneity, statistical tests erroneously detect heterogeneity
when there are few studies [2]. Another problem with this
model is that by adding a constant number to the weight of
each study, the relative contributions of each trial become
more equal. This can have a marked effect on the results, and
only seldom does it afford an appropriate representation of
the efficacy expected [3,4]. In fact, if we use a fixed effects
model then there is significant benefit with the use of APC in
both of the classic indications, namely Acute Physiology and
Chronic Health Evaluation II score above 25 (odds ratio 0.71,
95% confidence interval [CI] 0.56-0.91) and two or more
organ dysfunctions (odds ratio 0.78, 95% CI 0.64-0.94), with
the numbers needed to treat being 14 (95% CI 8-46) and 20
(95% CI 12-72), respectively.
The problem thus lies with the recognition of heterogeneity in
a trial, which includes clinical heterogeneity (variability in the
participants, interventions and outcomes), methodological
heterogeneity (variability in trial design and quality) and
statistical heterogeneity (variability in the treatment effects
evaluated in different trials). Ideally, a meta-analysis should
only be considered when a group of trials is sufficiently
homogeneous. Such a situation is Utopian. Indeed, one could
argue that because clinical and methodological diversity
always occur in a meta-analysis, statistical heterogeneity is
inevitable. Thus, the test for heterogeneity is irrelevant to the
choice of analysis; heterogeneity will always exist, whether
we are able to detect it using a statistical test or not [5].
Finally, the authors base their conclusions on an abstract
patient data meta-analysis rather than individual patient data
meta-analysis. Abstract patient data meta-analyses reflect the
first step toward generating hypotheses, which need to be
retested in a fully fledged individual patient data meta-analysis.
Although methodologically difficult, the latter can evaluate ran-
domization methods and correctness of data, re-analyze the
original data, perform additional analyses and update patient
outcomes that become ‘frozen’ in time, and can thus overcome
the limitations of abstract patient data meta-analysis [6].
Is there a role for APC in severe sepsis? The PROWESS
(Recombinant Human Activated Protein C Worldwide Evalua-
tion of Severe Sepsis) trial [7] demonstrated a 6.1% absolute
reduction in mortality rate (P = 0.005). Therefore, the use of
this drug should be continued in high-risk situations, as
defined by the Surviving Sepsis Campaign guidelines, unless
this recommendation is refuted in further trials.
Competing interests
The authors declare that they have no competing interests.
References
1. Friedrich JO, Adhikari NK, Meade MO: Drotrecogin alfa (acti-
vated): does current evidence support treatment for any
patients with severe sepsis? Crit Care 2006, 10:145.
2. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J:
Assessing Heterogeneity in Meta-Analysis: Q Statistic or I2
Index? Psychol Methods 2006, 11:193-206.
3. Ades AE, Lu G, Higgins JP: The interpretation of random-
effects meta-analysis in decision models. Med Decis Making
2005, 25:646-654.
4. Moayyedi P: Meta-analysis: can we mix apples and oranges?
Am J Gastroenterol 2004, 99:2297-2301.
5. Deeks JJ, Higgins JPT, Altman DG: Analysing and presenting
results. In: Cochrane Reviewers’ Handbook 422 [updated March
2004]. Edited by Alderson P, Green S, Higgins JPT. Chichester,
UK: John Wiley & Sons Ltd; 2004:68-139.
6. Piedbois P, Buyse M: Meta-analyses based on abstracted data:
a step in the right direction, but only a first step. J Clin Oncol
2004, 22:3839-3841.
7. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF,
Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand D, Ely
EW, for the Recombinant human protein C Worldwide Evaluation
in Severe Sepsis (PROWESS) study group: Efficacy and safety
of recombinant human activated protein C for severe sepsis.
N Engl J Med 2001, 344:699-709.
Letter
Activated protein C in sepsis: down but not out, yet
Ritesh Agarwal and Alok Nath
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Corresponding author: Ritesh Agarwal, ritesh@indiachest.org
Published: 26 July 2006 Critical Care 2006, 10:416 (doi:10.1186/cc4988)
This article is online at http://ccforum.com/content/10/4/416
© 2006 BioMed Central Ltd
See related commentary by Friedrich et al., http://ccforum.com/content/10/3/145